Haptoglobin-related protein as a serum marker in malignant lymphoma

Ron Epelbaum; Channa Shalitin; Ruth Segal; Clari Valansi; Ida Arselan; David Faraggi; Michelle Leviov; Menahem Ben-Shahar; Nissim Haim

doi:10.1007/BF02905217

Haptoglobin-related protein as a serum marker in malignant lymphoma

Ron Epelbaum, Channa Shalitin, Ruth Segal, Clari Valansi, Ida Arselan, David Faraggi, Michelle Leviov, Menahem Ben-Shahar, Nissim Haim

Department of Statistics

Research output: Contribution to journal › Article › peer-review

Abstract

A novel serum 21 kDa haptoglobin-related protein (Hpr) was investigated in patients with malignant lymphoma, to evaluate its correlation with clinical and histologic features at presentation and its possible role as a tumor marker for patient outcome. One hundred fifty eight serum samples were taken from 88 patients with non-Hodgkin's lymphoma (n=58) and Hodgkin's disease (n=30) at presentation and in the course of follow-up. Sera from 61 healthy volunteers served as normal controls. Serum Hpr levels in the lymphoma patients (median 430 x 10³ u/ml, range 0-4000 x 10³) were significantly higher than in the control group (median 68 x 10³ u/ml, range 0-180 x 10³) (p=0.0001). Higher median Hpr values were detected in patients with advanced disease (p=0.013), 'B' symptoms (p=0.029) and in males (p=0.053). There was also a significant correlation between Hpr and erythrocyte sedimentation rate (p=0.028). Serial determinations showed a significant decrease of the initial Hpr values obtained after treatment in 41 patients, 38 of whom achieved complete remission. In the follow-up period additional Hpr measurements were taken from 17 patients. Three of them eventually relapsed, and showed increased Hpr levels at the time of relapse. Hpr levels remained low in 11 of 14 patients who maintained complete remission, and increased in three. In conclusion, serum Hpr is a new serum tumor marker of potential use in the clinical setting of lymphoma.

Original language	English
Pages (from-to)	271-276
Number of pages	6
Journal	Pathology and Oncology Research
Volume	4
Issue number	4
DOIs	https://doi.org/10.1007/BF02905217
State	Published - 1998

Bibliographical note

Funding Information:
The outlook for lymphoma patients is heterogeneous. Although a substantial proportion of patients achieves complete remission, some of them may either do not response to treatment or experience relapse. The evaluation of the effectiveness of induction therapy is important, Received: August 12, 1998; accepted: Sept 30, 1998 Correspondence: Dr. Ron EPELBAUM, Department of Oncology, Rambam Medical Center, Haifa 31096, Israel; tel: 972-4-8543128, fax: 972-4-8542929 *This work is dedicated to the memory of Dr. Arie H. Bartal, a dedicated oncologist and friend. This work was supported by Chemotech Thechnologies Ltd., by grant no. 3676 from the Chief Scientist's Office of the Ministry of Health, Israel, and by the Fund for Promotion of Research in the Technion.

Keywords

21-kDa protein
ELISA
Haptoglobin-related protein
Lymphoma

ASJC Scopus subject areas

Pathology and Forensic Medicine
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/BF02905217

Cite this

@article{b63217be30de440196d2c819d4a087dd,

title = "Haptoglobin-related protein as a serum marker in malignant lymphoma",

abstract = "A novel serum 21 kDa haptoglobin-related protein (Hpr) was investigated in patients with malignant lymphoma, to evaluate its correlation with clinical and histologic features at presentation and its possible role as a tumor marker for patient outcome. One hundred fifty eight serum samples were taken from 88 patients with non-Hodgkin's lymphoma (n=58) and Hodgkin's disease (n=30) at presentation and in the course of follow-up. Sera from 61 healthy volunteers served as normal controls. Serum Hpr levels in the lymphoma patients (median 430 x 103 u/ml, range 0-4000 x 103) were significantly higher than in the control group (median 68 x 103 u/ml, range 0-180 x 103) (p=0.0001). Higher median Hpr values were detected in patients with advanced disease (p=0.013), 'B' symptoms (p=0.029) and in males (p=0.053). There was also a significant correlation between Hpr and erythrocyte sedimentation rate (p=0.028). Serial determinations showed a significant decrease of the initial Hpr values obtained after treatment in 41 patients, 38 of whom achieved complete remission. In the follow-up period additional Hpr measurements were taken from 17 patients. Three of them eventually relapsed, and showed increased Hpr levels at the time of relapse. Hpr levels remained low in 11 of 14 patients who maintained complete remission, and increased in three. In conclusion, serum Hpr is a new serum tumor marker of potential use in the clinical setting of lymphoma.",

keywords = "21-kDa protein, ELISA, Haptoglobin-related protein, Lymphoma",

author = "Ron Epelbaum and Channa Shalitin and Ruth Segal and Clari Valansi and Ida Arselan and David Faraggi and Michelle Leviov and Menahem Ben-Shahar and Nissim Haim",

note = "Funding Information: The outlook for lymphoma patients is heterogeneous. Although a substantial proportion of patients achieves complete remission, some of them may either do not response to treatment or experience relapse. The evaluation of the effectiveness of induction therapy is important, Received: August 12, 1998; accepted: Sept 30, 1998 Correspondence: Dr. Ron EPELBAUM, Department of Oncology, Rambam Medical Center, Haifa 31096, Israel; tel: 972-4-8543128, fax: 972-4-8542929 *This work is dedicated to the memory of Dr. Arie H. Bartal, a dedicated oncologist and friend. This work was supported by Chemotech Thechnologies Ltd., by grant no. 3676 from the Chief Scientist's Office of the Ministry of Health, Israel, and by the Fund for Promotion of Research in the Technion.",

year = "1998",

doi = "10.1007/BF02905217",

language = "English",

volume = "4",

pages = "271--276",

journal = "Pathology and Oncology Research",

issn = "1219-4956",

publisher = "Springer Netherlands",

number = "4",

}

TY - JOUR

T1 - Haptoglobin-related protein as a serum marker in malignant lymphoma

AU - Epelbaum, Ron

AU - Shalitin, Channa

AU - Segal, Ruth

AU - Valansi, Clari

AU - Arselan, Ida

AU - Faraggi, David

AU - Leviov, Michelle

AU - Ben-Shahar, Menahem

AU - Haim, Nissim

N1 - Funding Information: The outlook for lymphoma patients is heterogeneous. Although a substantial proportion of patients achieves complete remission, some of them may either do not response to treatment or experience relapse. The evaluation of the effectiveness of induction therapy is important, Received: August 12, 1998; accepted: Sept 30, 1998 Correspondence: Dr. Ron EPELBAUM, Department of Oncology, Rambam Medical Center, Haifa 31096, Israel; tel: 972-4-8543128, fax: 972-4-8542929 *This work is dedicated to the memory of Dr. Arie H. Bartal, a dedicated oncologist and friend. This work was supported by Chemotech Thechnologies Ltd., by grant no. 3676 from the Chief Scientist's Office of the Ministry of Health, Israel, and by the Fund for Promotion of Research in the Technion.

PY - 1998

Y1 - 1998

N2 - A novel serum 21 kDa haptoglobin-related protein (Hpr) was investigated in patients with malignant lymphoma, to evaluate its correlation with clinical and histologic features at presentation and its possible role as a tumor marker for patient outcome. One hundred fifty eight serum samples were taken from 88 patients with non-Hodgkin's lymphoma (n=58) and Hodgkin's disease (n=30) at presentation and in the course of follow-up. Sera from 61 healthy volunteers served as normal controls. Serum Hpr levels in the lymphoma patients (median 430 x 103 u/ml, range 0-4000 x 103) were significantly higher than in the control group (median 68 x 103 u/ml, range 0-180 x 103) (p=0.0001). Higher median Hpr values were detected in patients with advanced disease (p=0.013), 'B' symptoms (p=0.029) and in males (p=0.053). There was also a significant correlation between Hpr and erythrocyte sedimentation rate (p=0.028). Serial determinations showed a significant decrease of the initial Hpr values obtained after treatment in 41 patients, 38 of whom achieved complete remission. In the follow-up period additional Hpr measurements were taken from 17 patients. Three of them eventually relapsed, and showed increased Hpr levels at the time of relapse. Hpr levels remained low in 11 of 14 patients who maintained complete remission, and increased in three. In conclusion, serum Hpr is a new serum tumor marker of potential use in the clinical setting of lymphoma.

AB - A novel serum 21 kDa haptoglobin-related protein (Hpr) was investigated in patients with malignant lymphoma, to evaluate its correlation with clinical and histologic features at presentation and its possible role as a tumor marker for patient outcome. One hundred fifty eight serum samples were taken from 88 patients with non-Hodgkin's lymphoma (n=58) and Hodgkin's disease (n=30) at presentation and in the course of follow-up. Sera from 61 healthy volunteers served as normal controls. Serum Hpr levels in the lymphoma patients (median 430 x 103 u/ml, range 0-4000 x 103) were significantly higher than in the control group (median 68 x 103 u/ml, range 0-180 x 103) (p=0.0001). Higher median Hpr values were detected in patients with advanced disease (p=0.013), 'B' symptoms (p=0.029) and in males (p=0.053). There was also a significant correlation between Hpr and erythrocyte sedimentation rate (p=0.028). Serial determinations showed a significant decrease of the initial Hpr values obtained after treatment in 41 patients, 38 of whom achieved complete remission. In the follow-up period additional Hpr measurements were taken from 17 patients. Three of them eventually relapsed, and showed increased Hpr levels at the time of relapse. Hpr levels remained low in 11 of 14 patients who maintained complete remission, and increased in three. In conclusion, serum Hpr is a new serum tumor marker of potential use in the clinical setting of lymphoma.

KW - 21-kDa protein

KW - ELISA

KW - Haptoglobin-related protein

KW - Lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0032455280&partnerID=8YFLogxK

U2 - 10.1007/BF02905217

DO - 10.1007/BF02905217

M3 - Article

C2 - 9887357

AN - SCOPUS:0032455280

SN - 1219-4956

VL - 4

SP - 271

EP - 276

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

IS - 4

ER -

Haptoglobin-related protein as a serum marker in malignant lymphoma

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this